Source-grounded facts extracted from Insight Molecular Diagnostics Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Insight Molecular Diagnostics Inc. shareholders approved To approve an amendment to the Amended and Restated 2018 Equity Incentive Plan to increase the total number of shares of the Company’s common stock authorized for issuance under the Incentive Plan by 1,750,000, to a total of 5,550,000 shares at the 2026-06-11 meeting.
“Approval of Amendment to Incentive Plan Shares Non-Votes 19,117,865 122,829 4,799 4,708,719”
Insight Molecular Diagnostics Inc. shareholders approved To approve, on a non-binding advisory basis, the Company’s named executive officer compensation for the year ended December 31, 2025 at the 2026-06-11 meeting.
“Say On Pay Proposal Shares Non-Votes 19,199,697 26,126 19,679 4,708,719”
Insight Molecular Diagnostics Inc. shareholders approved To ratify the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-11 meeting.
“Ratification of Appointment of Accounting Firm Shares Non-Votes 23,949,191 2,420 2,601 0”
Insight Molecular Diagnostics Inc. shareholders approved To elect the following four (4) director nominees, each to serve until the 2027 annual meeting of shareholders and until his successor has been elected and qualified, or until his earlier death, resignation, or removal: Joshua Riggs, Andrew Arno, Andrew J. Last and Louis E. Silverman at the 2026-06-11 meeting.
“Shares Voted Director Nominee For Against Abstained Broker Non-Votes Joshua Riggs 19,239,253 2,420 3,820 4,708,719 Andrew Arno 19,100,993 140,445 4,056 4,708,719 Andrew J. Last 19,237,621 3,938 3,935 4,708,719 Louis E. Silverman 19,224,148 17,290 4,056 4,708,719”
Insight Molecular Diagnostics Inc. entered into Specimen Collection Agreement with Quest Diagnostics Incorporated (effective 2026-02-20).
“On February 20, 2026, Insight Molecular Diagnostics Inc. (the “Company”) entered into a Specimen Collection Agreement (the “Agreement”) with Quest Diagnostics Incorporated (“Quest Diagnostics”).”
Insight Molecular Diagnostics Inc. entered into Placement Agency Agreement with Lake Street Capital Markets, LLC (effective 2026-02-10).
“The Company entered into a placement agency agreement (the “ Placement Agency Agreement ”), dated as of February 10, 2026, with Lake Street Capital Markets, LLC (the “ Placement Agent ”), pursuant to which the Placement Agent agreed to serve as the placement agent for the Company in connection with the Offering.”
Insight Molecular Diagnostics Inc. entered into Purchase Agreements with certain institutional investors valued at approximately $24.5 million (effective 2026-02-10).
“On February 10, 2026, Insight Molecular Diagnostics Inc. (the “ Company ”) entered into securities purchase agreements (the “ Purchase Agreements ”) with certain institutional investors, pursuant to which the Company agreed to issue and sell (i) 3,482,498 shares (the “ Shares ”) of the Company’s common stock, no par value per share (the “ Common Stock ”), and (ii) Pre-Funded Warrants (the “ Pre-Funded Warrants ”) to purchase up to 1,043,478 shares of Common Stock (the “ Pre-Funded Warrant Shares ”) in a registered direct offering (the “ Offering ”), pursuant to an effective shelf registration statement on Form S-3 (File No. 333-281159), a base prospectus and prospectus supplement relating to the Offering (the “ Prospectus Supplement ”), in each case filed with the Securities and Exchange Commission.”
Insight Molecular Diagnostics Inc.: Amended and restated bylaws (Third Amended and Restated Bylaws) solely to reflect the company name change (effective 2025-06-13).
“Also on June 13, 2025, the Company amended and restated the Company’s Second Amended and Restated Bylaws (the “Third Amended and Restated Bylaws”) solely to reflect the Name Change.”
Insight Molecular Diagnostics Inc.: Amended Article I of Articles of Incorporation to change company name from Oncocyte Corporation to Insight Molecular Diagnostics Inc (effective 2025-06-13).
“In connection with the Name Change, the Company filed a Certificate of Ownership with the Secretary of State of the State of California on June 13, 2025, to amend Article I of the Company’s Articles of Incorporation solely to reflect the Company’s new corporate name.”
Insight Molecular Diagnostics Inc. engaged CBIZ CPAs P.C. as its auditor.
“engaged CBIZ CPAs on April 16, 2025 as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025”
Insight Molecular Diagnostics Inc. dismissed Marcum LLP as its auditor.
“On April 11, 2025, the Company terminated its relationship with Marcum as the Company’s independent registered public accounting firm”
James Liu changed role as Vice President Accounting, Controller, Treasurer and Principal Accounting Officer at Insight Molecular Diagnostics Inc..
“On March 4, 2025, the Company promoted James Liu to Vice President Accounting, Controller, Treasurer and Principal Accounting Officer, effective March 10, 2025.”
Andrea James was appointed as Chief Financial Officer at Insight Molecular Diagnostics Inc..
“On June 17, 2024, the Board of Directors (the “Board”) of Oncocyte Corporation (the “Company”) appointed Andrea James to serve as the Company’s Chief Financial Officer, effective June 17, 2024.”
Insight Molecular Diagnostics Inc. reported the quarter ended March 31, 2024 results: revenue $176,000.
“Net revenue for the three months ended March 31, 2024 was $176,000, a decrease of 41% compared to the same period in 2023, due to decreased revenue from our Pharma Services business.”
Insight Molecular Diagnostics Inc. reported year ended December 31, 2023 results: revenue $1.5 million.
“commercial and regulatory milestones.” 2023 Fourth Quarter and Full-Year Financial Results Net revenue for the three months and year ended December 31, 2023, was $314,000 and $1.5 million, respectively, an increase of 15% compared to the fourth quarter 2022 and 57% compared to the full year 2022, due to increased revenue from Pharma Services. Cost of revenues for”
Insight Molecular Diagnostics Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $15.8 million (effective 2024-04-11).
“On April 11, 2024, Oncocyte Corporation (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors (collectively, the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement”) of an aggregate of 5,077,387 shares (the “Common Shares”) of common stock of the Company, no par value per share (the “Common Stock”), and pre-funded warrants (“Pre-Funded Warrants”) to purchase up to 342,888 shares of Common Stock, with an exercise price of $0.0001 per share.”
Insight Molecular Diagnostics Inc. entered into Collaboration Agreement with Bio-Rad Laboratories, Inc. (effective 2024-04-05).
“On April 5, 2024, Oncocyte Corporation (the “Company”) entered into a Collaboration Agreement with Bio-Rad Laboratories, Inc. (“Bio-Rad”) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents (the “Collaboration Agreement”).”
Insight Molecular Diagnostics Inc. reported third quarter ended September 30, 2023 results: revenue $0.4 million, net income $6.5 million net consolidated operating loss.
“for growth in 2024 and the years beyond,” concluded Mr. Riggs. Third Quarter 2023 Financial Results Consolidated revenue for the third quarter of 2023 was approximately $0.4 million primarily due to increased revenue from Pharma Services. Cost of revenue was approximately $0.2 million. Net consolidated operating loss for the three months ended September 30,”
Insight Molecular Diagnostics Inc. engaged Marcum LLP as its auditor.
“the Company is filing this amendment to the above-referenced Form 8-K to disclose that on October 10, 2023, Marcum completed its client acceptance procedures and provided the Company with a fully executed engagement letter.”
Insight Molecular Diagnostics Inc. engaged Marcum LLP as its auditor.
“the Audit Committee approved the engagement of Marcum LLP (“ Marcum ”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, subject to Marcum’s completion of their client acceptance procedures.”
Insight Molecular Diagnostics Inc. dismissed WithumSmith+Brown, PC as its auditor.
“The Company has dismissed WithumSmith+Brown, PC (“ Withum ”) as independent registered public accounting firm of the Company on September 29, 2023.”
Insight Molecular Diagnostics Inc. entered into Sublease Agreement with Induce Biologics USA, Inc. valued at Monthly base rent starting at $36,850.00, security deposit of $101,987.38 (effective 2023-09-14).
“On August 8, 2023, Oncocyte Corporation (the “ Company ”) and Induce Biologics USA, Inc. (“ Subtenant ”) entered into a Sublease Agreement (the “ Sublease Agreement ”), which subsequently became effective as of September 14, 2023, upon the execution and delivery by the Company, Subtenant, and Cushing Ventures, LLC (“ Landlord ”), of that certain Landlord’s Consent to Sublease dated September 12, 2023 (the “ Consent Agreement ”), under which Landlord consented to the Sublease Agreement, on the terms and subject to the conditions set forth therein.”
Insight Molecular Diagnostics Inc. reported Second Quarter 2023 results: revenue 0.5 million.
“Consolidated revenues for the second quarter of 2023 were approximately $0.5 million, and cost of revenues for the second quarter were approximately $0.2 million, primarily from services customers.”
James Liu was appointed as interim Principal Financial Officer at Insight Molecular Diagnostics Inc..
“On that same date, the Company appointed Mr. Liu to the additional role of interim Principal Financial Officer.”
James Liu changed role as Senior Director, Controller & Principal Accounting Officer at Insight Molecular Diagnostics Inc..
“On August 4, 2023, the Company promoted James Liu to Senior Director, Controller & Principal Accounting Officer.”
Insight Molecular Diagnostics Inc.: The Company filed a Certificate of Amendment to effect a 1-for-20 reverse stock split, effective July 24, 2023, to regain Nasdaq minimum bid price compliance (effective 2023-07-24).
“The Company filed a Certificate of Amendment of Articles of Incorporation (the “ Certificate of Amendment ”) with the Secretary of State of the State of California to effect the reverse stock split (but not the authorized share reduction). The reverse stock split will become effective as of 5:00 p.m. Pacific time on July 24, 2023 (the “ Effective Time ”).”
Insight Molecular Diagnostics Inc. shareholders approved To approve an amendment to the Company’s 2018 Equity Incentive Plan (as amended, the “Incentive Plan”) to eliminate the limitation on the number of shares of Common Stock that can be granted to any individual participant under the Incentive Plan during any one-year period at the 2023-07-24 meeting.
“The shareholders of the Company approved Proposal No. 3 approving the amendment to the Incentive Plan by the following vote:”
Insight Molecular Diagnostics Inc. shareholders approved To approve granting the Board the authority to exercise its discretion at any time within one year after shareholder approval is obtained to amend the Company’s Articles of Incorporation to reduce the number of authorized shares of Common Stock by a corresponding ratio to the reverse stock split if, at the 2023-07-24 meeting.
“The shareholders of the Company approved Proposal No. 2 granting the Board the authority to effect a reduction of the authorized shares of Common Stock by the following vote:”
Insight Molecular Diagnostics Inc. shareholders approved To approve granting the Board the authority to exercise its discretion to amend the Company’s Articles of Incorporation to effect a reverse stock split of its outstanding shares of the Common Stock to regain compliance with The Nasdaq Stock Market’s minimum bid price requirement, at any of the follo at the 2023-07-24 meeting.
“The shareholders of the Company approved Proposal No. 1 granting the Board the authority to effect a reverse stock split at any of the proposed ratios, including a ratio of one-for- twenty, in each case, by the vote set forth below:”
Insight Molecular Diagnostics Inc. shareholders approved To approve, on an advisory basis, the Company’s named executive officer compensation in fiscal 2022. at the 2023-06-23 meeting.
“3. Advisory Vote to Approve Named Executive Officer Compensation Shares Voted For Against Abstained Broker Non-Votes 78,956,918 5,312,531 127,814 43,376,020”
Insight Molecular Diagnostics Inc. shareholders approved To ratify the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accountants for the fiscal year ending December 31, 2023. at the 2023-06-23 meeting.
“2. Ratification of Independent Registered Public Accounting Firm Shares Voted For Against Abstained Broker Non-Votes 126,399,465 714,459 659,359 0”
Insight Molecular Diagnostics Inc. shareholders approved To elect five (5) directors to hold office until the next annual meeting of shareholders and until their respective successors are duly elected and qualified. at the 2023-06-23 meeting.
“1. Election of Directors Shares Voted Director Nominee For Withheld Broker Non-Votes Joshua Riggs 83,530,246 867,017 43,376,020 Andrew Arno 83,418,588 978,675 43,376,020 Alfred D. Kingsley 78,869,742 5,527,521 43,376,020 Andrew J. Last 80,339,227 4,058,036 43,376,020 Louis E. Silverman 82,542,629 1,854,634 43,376,020”
Joshua Riggs was appointed as Chief Executive Officer at Insight Molecular Diagnostics Inc..
“On March 2, 2023, Oncocyte Corporation (the “Company”) issued a press release announcing that Joshua Riggs, the Interim Chief Executive Officer of the Company, was appointed the Chief Executive Officer of the Company, effective February 24, 2023”
Insight Molecular Diagnostics Inc. reported the three months ended March 31, 2023 results: revenue $0.7 million, net income $2.9 million.
“to create value for both patients and shareholders.” First Quarter 2023 Financial Results Consolidated revenues for the three months ended March 31, 2023, were approximately $0.7 million, a 50% decrease compared to the first quarter of 2022. Excluding DetermaRx revenue, the continuing operations revenue was $0.3 million for the three months ended March 31, 2023.”
Anish John resigned as Chief Financial Officer at Insight Molecular Diagnostics Inc..
“On May 11, 2023, Oncocyte announced that Anish John, our Chief Financial Officer, will be leaving the Company on June 15, 2023.”
Insight Molecular Diagnostics Inc. announced a restructuring with charges of approximately $0.3 million related to employee severance and benefits costs affecting workforce (approximately 20% of its workforce).
“On April 12, 2023, Oncocyte Corporation (the “Company” or “Oncocyte”) , announced a reduction in force involving approximately 20% of its workforce (the “Reduction”), which management believes will extend Oncocyte’s cash runway in 2024. In connection with the Reduction, Oncocyte estimates that it will incur charges of approximately $0.3 million related to employee severance and benefits costs in the second quarter of 2023.”
Insight Molecular Diagnostics Inc. reported financial results for the year ended December 31, 2022.
“The financial information provided in this Current Report on Form 8-K (this “Current Report”) that relates to the results of operations or financial condition of Oncocyte Corporation (the “Company,” “Oncocyte,” “we,” “us” or “our”) for the year ended December 31, 2022 is hereby incorporated by reference into this Item 2.02.”
Insight Molecular Diagnostics Inc. reported the full year ended December 31, 2022 results: revenue approximately $1.1 million and $5.6 million, respectively.
“dossier to MolDx in December 2022 2022 Preliminary Financial Results Consolidated revenues for the three and twelve months ended December 31, 2022, were approximately $1.1 million and $5.6 million, respectively, a decrease of 69% compared to fourth quarter 2021 and 27% compared to the full year 2021. Excluding DetermaRx revenue, the continuing”
Joshua Riggs was appointed as Director at Insight Molecular Diagnostics Inc..
“Mr. Riggs has also been appointed President and joined the Company’s Board of Directors effective February 28, 2023.”
Joshua Riggs was appointed as President at Insight Molecular Diagnostics Inc..
“Mr. Riggs has also been appointed President and joined the Company’s Board of Directors effective February 28, 2023.”
Joshua Riggs was appointed as Chief Executive Officer at Insight Molecular Diagnostics Inc..
“Effective February 24, 2023, the Board of Directors of Oncocyte Corporation (“Oncocyte” or the “Company”) appointed Joshua Riggs as Chief Executive Officer of the Company.”
Insight Molecular Diagnostics Inc. shareholders rejected to approve an amendment (the "Plan Amendment") to the Company's 2018 Equity Incentive Plan (the "Incentive Plan") to eliminate "fungible share counting" at the 2022-07-15 meeting.
“As disclosed in the Original Report, the voting results for Proposal No. 5 were as follows: Shares Voted For Against Abstained Broker Non-Votes 42,563,690 30,005,136 218,250 21,793,461 Accordingly, because the 42,563,690 votes cast in favor of Proposal No. 5 at the Meeting did not constitute a majority of the shares represented at the Meeting, Proposal No. 5 to approve the Plan Amendment was not approved by the Company's shareholders at the Meeting, and the statements in the Original Report to the contrary were made in error and are updated as set forth in this Amendment.”
Insight Molecular Diagnostics Inc. terminated Collaboration Agreement with Life Technologies Corporation, a Delaware corporation and subsidiary of Thermo Fisher Scientific Inc. (effective 2023-02-07).
“On February 7, 2023, Oncocyte entered into a Termination Agreement (the “Termination Agreement”) with Life Technologies Corporation, a Delaware corporation and subsidiary of Thermo Fisher Scientific Inc. (“LTC” and together with Oncocyte, the “Parties” or individually, a “Party”), pursuant to which the Parties agreed to terminate that certain Collaboration Agreement dated January 13, 2022, by and between Oncocyte and LTC (the “Collaboration Agreement”).”
Insight Molecular Diagnostics Inc. amended Amendment No. 1 to the Merger Agreement (effective 2023-02-08).
“On February 8, 2023, the Company and equityholder representative entered into Amendment No. 1 to the Merger Agreement (the “Amendment”), pursuant to which the parties agreed that (i) Chronix’s equity holders will be paid earnout consideration of 10% of net collections for sales of specified tests and products, until the expiration of intellectual property related to such tests and products, (ii) Chronix’s equity holders will be paid 5% of the gross proceeds received from any sale of all or substantially all of the rights, titles, and interests in and to Chronix’s patents for use in transplantation medicine to such third party, and (iii) the Milestone Payments, 15% Royalty and Transplant Transfer Payout obligations were eliminated.”
Insight Molecular Diagnostics Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)(ii)).
“February 7, 2023. The Company’s common stock continues to trade under the symbol “OCX”. The Nasdaq Capital Market operates in substantially the same manner as The Nasdaq Global Market, with issuers listed on The Nasdaq Capital Market tier required to meet certain financial and corporate governance requirements to qualify for continued listing. On February 7, 2023, the Company received confirmation that Nasdaq has determined that the Company is eligible for an additional 180-calendar day period to regain compliance by meeting the minimum bid price requirement. The minimum bid price requirement”
Insight Molecular Diagnostics Inc. amended First Amendment to Stock Purchase Agreement with Dragon Scientific, LLC valued at Extended the Outside Date from February 1, 2023 to February 15, 2023 (effective 2023-01-30).
“On January 30, 2023, the Company, Buyer and Razor entered into a First Amendment to Stock Purchase Agreement whereby the parties agreed to the extend the Outside Date, as set forth in Section 3.1(e) of the Agreement, to February 15, 2023 (“First Amendment”). No other provisions of the Agreement were otherwise amended or waived by the First Amendment, and the Agreement remains in full force and effect.”
Insight Molecular Diagnostics Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5450(a)(1), 5810(c)(3)(A)(ii)).
“August 9, 2022 indicating that Nasdaq had determined that the Company no longer meets the minimum bid price requirement of Nasdaq Listing Rule 5450(a)(1), as the minimum closing bid price for the Company’s common stock was less than $1.00 for the previous 30 consecutive business days. The Notice provided that the Company may consider applying to transfer the listing of the Company’s common stock to The Nasdaq Capital Market, subject to the Company submitting an online transfer application, paying the requisite fee, satisfying such market’s continued listing requirement for the market value of”
Insight Molecular Diagnostics Inc. announced a restructuring with charges of charges of over approximately $1.0 million related to employee severance and benefits costs affecting over 40% of its full-time employees (over 40% of its full-time employees).
“On December 16, 2022, Oncocyte announced a reduction in force involving over 40% of its full-time employees (the “Reduction”), which Oncocyte expects will decrease its annualized headcount carrying costs by over approximately $10 million, exclusive of related employee severance and benefit costs (as described further below). The Reduction began on December 16, 2022 and is expected to be completed in February 2023. In connection with the Reduction, we estimate that we will incur charges of over approximately $1.0 million related to employee severance and benefits costs.”
Insight Molecular Diagnostics Inc. entered into Stock Purchase Agreement with Dragon Scientific, LLC valued at 3,188,181 shares of common stock of Razor, constituting approximately 70% of the issued and outstand (effective 2022-12-15).
“On December 15, 2022, Oncocyte Corporation, a California corporation (“Oncocyte” or the “Company”), entered into a Stock Purchase Agreement (the “Agreement”) with Dragon Scientific, LLC, a Delaware limited liability company (“Buyer”), and Razor Genomics Inc., a Delaware corporation and wholly-owned subsidiary of Oncocyte (“Razor”). Pursuant to the Agreement, Oncocyte agreed to sell, and Buyer agreed to purchase, 3,188,181 shares of common stock of Razor, which constitutes approximately 70% of the issued and outstanding equity interests of Razor on a fully-diluted basis. Following the closing of the transaction (the “Closing”), Oncocyte will own 1,366,364 shares of common stock of Razor, which will constitute approximately 30% of the issued and outstanding equity interests of Razor on a fully-diluted basis. Razor holds an exclusive worldwide license from The University of California San Francisco under certain patent rights applicable to DetermaRxTM, which is used to predict a patient’s”
Douglas Ross departed as Chief Scientific Officer at Insight Molecular Diagnostics Inc..
“the positions occupied by Gisela Paulsen, President and Chief Operating Officer, and Douglas Ross, Chief Scientific Officer, will be eliminated.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.